The global prokaryotic recombinant protein market is poised to register a CAGR of 7.4% CAGR from 2023 to 2033. According to Future Market Insights, a valuation of US$ 2.8 billion is expected in the year 2023, and will eventually grow at the aforementioned rate to reach US$ 5.7 billion. Prokaryotic recombinant proteins are proteins encrypted by a gene (recombinant DNA) and cloned in a prokaryotic system (E. coli). High specificity and low immunogenicity of prokaryotic recombinant proteins make them suitable candidate for chronic therapies and several autoimmune disorders.
Monoclonal antibodies form the largest segment of the recombinant protein market. According to the World Health Organization (WHO), chronic diseases (Diabetes, Cancers, Cardiovascular diseases and others), will become 7th leading cause of death worldwide by 2030. This will fuel the growth of prokaryotic recombinant protein market by virtue of their greater benefits and minimal side effects in treating chronic and autoimmune diseases.
Recombinant proteins have a broad range of applications from basic research to pharmaceutical development. Of utmost importance in the production of recombinant proteins is the selection of the best recombinant protein production system, such that high-quality and functional recombinant proteins are produced. Plants can produce a large quantity of recombinant proteins rapidly and economically.
Glycoengineering has created “humanized” plant lines that can produce glycoproteins with specific human glycans with a high level of homogeneity on demand. Here, a detailed protocol was provided to produce a large, multisubunit, and complex bispecific antibody that targets two distinct viruses. The successful production of this multiple-subunit protein demonstrated that plants are the optimal system for the production of recombinant proteins of various sizes and complexity, which can be employed for various applications including diagnostics, therapeutics, and vaccines to combat current and future pandemics.
Recombinant proteins are important tools for studying biological processes. Generating a recombinant protein requires the use of an expression system. Selection of an appropriate expression system is dependent on the characteristics and intended application of the recombinant protein and is essential to produce sufficient quantities of the protein. Over the last 30 years, there have been considerable advances in the technologies for expressing recombinant proteins. In this chapter the unique characteristics of four commonly used expression systems, Escherichia coli, Pichia pastoris, baculovirus/insect cell, and mammalian cells are described. The E. coli system is a rapid method for expressing proteins but lacks many of the posttranslational modifications found in eukaryotes.
The benefits of this system include rapid growth, high density in simple and cost-effective cell culture media, well-known genetic information, the availability of a large number of cloning carriers and host mutated strains, simple transfection, easy control of its promoter, and mass production of the recombinant proteins. However, the prokaryotic system has some drawbacks. One of them is high cell density due to acetate formation, leading to toxicity. Also, proteins produced in inclusion bodies are often insoluble and need to be refolded.
This system is unable to produce proteins possessing high disulphide bridges. Other limitations of prokaryotic expression systems include the lack of post-translational modifications, such as protein glycation, changes or replacement of amino acids due to codon preference, endotoxin contamination, destruction of external protein inserted into the host, incorrect processing due to lack of chaperones, production of inactive proteins, instability of plasmids, production of small amounts of functional proteins, accumulation of recombinant products as inclusion bodies, and difficulty in protein purification.
| Data Points | Key Statistics |
|---|---|
| Anticipated Market Value of Prokaryotic Recombinant Proteins in 2023 | US$ 2.8 billion |
| Projected Value of Prokaryotic Recombinant Protein Market in 2033 | US$ 5.7 billion |
| Global Growth Rate (2023 to 2033) | CAGR of 7.4% |
Prokaryotic recombinant proteins are proteins encrypted by a gene (recombinant DNA) and cloned in a prokaryotic system (E.coli). High specificity and low immunogenicity of prokaryotic recombinant proteins make them suitable candidate for chronic therapies and several autoimmune disorders.
Monoclonal antibodies form the largest segment of the recombinant protein market. According to the World Health Organization (WHO), chronic diseases (Diabetes, Cancers, Cardiovascular diseases and others), will become 7th leading cause of death worldwide by 2030. This will fuel the growth of prokaryotic recombinant protein market by virtue of their greater benefits and minimal side effects in treating chronic and autoimmune diseases.
The high specificity and low immunogenicity of prokaryotic recombinant proteins make them the choice of treatment in a variety of chronic diseases. Moreover, increasing prevalence and incidence of chronic diseases such as diabetes, cancers and other autoimmune disorders are also going to drive prokaryotic recombinant protein market.
Rising inclination towards the biologics will speed up the growth of prokaryotic recombinant protein market. However, the high cost of the prokaryotic recombinant proteins will restrain the growth of the market in the forecast period. Besides, rising demand for biosimilars will also restrict the growth of prokaryotic recombinant protein market globally.
Prokaryotic recombinant protein market is growing at a rapid pace owing to the huge investments in research and development. The major players in the prokaryotic recombination protein market are collaborating to build upon the research and commercialization expertise. For instance, in 2013, GVK Biosciences collaborated with USA-based Endo Pharma for using its research expertise whereas Endo will distribute the former's products in the global market.
In another setting, Novasep partnered with GTP in 2016 for robust production of monoclonal antibodies and recombinant proteins.
With the rise in the prevalence of the chronic disease, monoclonal antibodies will contribute the largest revenue share for prokaryotic recombinant proteins. It is expected that the use of monoclonal antibodies will be extensively used in the treatment of diabetes, cardiac problems and cancers that will lead to the growth of the prokaryotic recombinant proteins market.
North America will drive the Prokaryotic recombinant protein market due to technological advancement and world-class research institutes in the USA and Canada. High prevalence of chronic diseases along with the development of new products in this region will trigger the growth of prokaryotic recombinant protein market. After North America, Prokaryotic recombinant protein market is then followed by due to the rising ageing population.
The strong healthcare payer-provider structure will fuel the growth of prokaryotic recombinant protein market. Asia-Pacific is estimated to show significant growth for Prokaryotic recombinant protein market due to rising prevalence diabetic population in India and China. Africa, Latin America and Middle East regions are expected to show slower growth for Prokaryotic recombinant protein market due to lack of awareness among the people in this region.
Examples of some of the market participants in Prokaryotic recombinant protein market identified across the value chain Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche AG, Prospec-Tany Technogene Ltd, Cusabio Technology LLC., Randox Laboratories Ltd, Batavia Biosciences, Geno Technology Inc., Kaneka and Eurogentec S.A., Abnova Corporation, Cayman Chemical Company., Geltor IndieBio, Bioclone Inc., and others.
The key players building upon their capabilities by collaborating with firms having core expertise. For instance, in 2019, Genscript Biotech collaborated with REMD Biotherapeutics to develop and commercialize several bispecific antibodies.
The research report on Prokaryotic recombinant protein market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on Prokaryotic recombinant protein market provides analysis and information according to market segments such as geographies, application, and industry.
The report on Prokaryotic recombinant protein market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global Prokaryotic recombinant protein market is classified on the basis of product type, therapy area, application and end user.
Explore Similar Insights
Prokaryotic Recombinant Protein Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
